



Regioselective Halogenation of 1,4-Benzodiazepinones via CH Activation

Hajer Abdelkafi, Jean-Christophe Cintrat

► **To cite this version:**

Hajer Abdelkafi, Jean-Christophe Cintrat. Regioselective Halogenation of 1,4-Benzodiazepinones via CH Activation. Scientific Reports, Nature Publishing Group, 2015, 5 (1), <https://www.nature.com/articles/srep12131> . 10.1038/srep12131 . cea-02075732

HAL Id: cea-02075732

<https://hal-cea.archives-ouvertes.fr/cea-02075732>

Submitted on 21 Mar 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

SCIENTIFIC REPORTS



OPEN

Regioselective Halogenation of 1,4-Benzodiazepinones via CH Activation

Hajer Abdelkafi & Jean-Christophe Cintrat

Received: 13 January 2015

Accepted: 15 June 2015

Published: 16 July 2015

This article reports an efficient CH activation process for regioselective halogenation of 1,4-benzodiazepinones. Direct halogenation with NXS (X = Br, I) affords halogenated benzodiazepinones on the central aromatic ring whereas catalyst (Pd(OAc)₂) controlled CH activation furnishes regioselectively ortho halogenated benzodiazepinones on the phenyl side chain.

Over the past decade, Pd(II)-catalyzed halogenation of CH bond guided by an intramolecular directing group has emerged as an efficient method in organic synthesis. Different halogenating reagents and directing groups have been employed for the direct transformation of C-H bond to C-X (X = Cl, Br, I) bond^{1–9}. During our studies on 1,4-benzodiazepinones as bioactive molecules on different targets^{10–12} we were interested in developing direct halogenation taking advantage of the internal ketimine to direct the CH activation. It has been proven that the presence of halogen atoms at the 2' and/or 7 position, for 1,4-benzodiazepinones acting as GABA receptor allosteric modulators, result in increased receptor affinity¹³. Hence few marketed psychotropes are halogenated 1,4-benzodiazepinones (Fig. 1)¹⁴.

To the best of our knowledge, no direct introduction of halogen atoms at the 2' position of the 1,4-benzodiazepinone skeleton has been described. Designing such a route from the already synthesized benzodiazepinones would allow a quick entry to halogenated analogues or functionalized derivatives via metal catalyzed cross-coupling reactions.

A direct CH activation of this ortho position could be a straightforward route to halogenated benzodiazepinones. We were encouraged in this approach based on recent reports that described the synthesis of 1,4-benzodiazepinones derived metallacycles with either zinc¹⁵, palladium^{16–18} or ruthenium¹⁹. Here we report a direct halogenation of 1,4-benzodiazepinones via a catalytic CH activation.

Results and discussion

The palladium-catalyzed directed CH activation/halogenation reactions on model compounds usually proceed in good yield and with complete control of regioselectivity⁹. We therefore started with unsubstituted benzodiazepinone **1** to find the best experimental conditions to get halogenation of the C phenyl ring with minimum amount of side reaction on the A phenyl ring. Microwave heating was preferred to conventional heating to lower the reaction time and the amount of degradation compounds.

Few palladium catalysts were initially tested with NIS as halogenating agent but only palladium acetate afforded the halogenated compound albeit with low yield. Reaction performed in acetonitrile with 1.5 equivalents of NIS at 80 °C for 15 minutes afforded solely the monohalogenated compound **1-I** (Table 1, entry 1). Raising the reaction temperature to 100 °C fully converted the starting material but 15% of the 2',6'-dihalogenated compound **1-II** was also observed (Table 1, entry 2). Upon warming to 120 °C dimerization of the starting material was observed along with degradation (Table 1, entry 3). Finally reaction at 100 °C without palladium catalyst never yielded iodination even with two equivalents of NIS and prolonged reaction time (Table 1, entries 4 and 5).

The ortho position of the iodine was assigned by NMR analysis and unambiguously confirmed from X-Ray crystallography (see Fig. 2).

CEA, iBiTecS, Service de Chimie Bioorganique et de Marquage, LabEx LERMIT. 91191 Gif-sur-Yvette (France). Correspondence and requests for materials should be addressed to J.C.C. (email: jean-christophe.cintrat@cea.fr)





Figure 1. Examples of halogenated 1,4-benzodiazepinones and marketed drugs.



Entry	Halogenating agent	Equivts	Catalyst	Solvent	Temperature (°C)	Time (min)	Product	Conversion (%) ^a
1	NIS	1.5	Pd(OAc) ₂	CH ₃ CN	80	15	1-I	50
2	NIS	1.5	Pd(OAc) ₂	CH ₃ CN	100	15	1-I:1-II	85:15
3	NIS	1.5	Pd(OAc) ₂	CH ₃ CN	120	15	-	- ^b
4	NIS	2	-	CH ₃ CN	100	15	-	-
5	NIS	2	-	CH ₃ CN	100	60	-	-
6	NBS	3	Pd(OAc) ₂	CH ₃ CN	100	20	1-Br:2	47:5
7	NBS	5	Pd(OAc) ₂	DMF	100	60	1-Br:2	54:23
8	NBS	5	-	DMF	100	60	2	50
9	CuBr ₂	2	Pd(OAc) ₂	CH ₃ CN	100	20	-	-

Table 1. Screening of experimental conditions for the ortho halogenation of benzodiazepinones.

^aconversions were determined by LC/MS. ^bdegradation was observed.

Surprisingly, a drop of reactivity was observed when NBS and NCS were used as halogenating agents. Using the previously optimized conditions in the presence of NBS gave less conversion to **1-Br** (50% of starting material left) along with some brominated compound on the central phenyl ring **2** (Table 1, entry 6). Increasing the amount of NBS to 5 equivalents, prolonged heating (1 hour) and replacing CH₃CN by DMF resulted in more compound **2** (Table 1, entry 7). Interestingly, reaction performed without palladium acetate only resulted in compound **2** (Table 1, entry 8). To the best of our knowledge, no direct halogenation of 1,4-benzodiazepinone on the 7-position was reported (compound **2**). The 7-bromo position was unequivocally identified by comparison with NMR spectra of 7-bromo-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one obtained from 2-amino-4-bromobenzophenone. This regioselective control affords a straightforward access to 7-brominated benzodiazepinones. Replacing NBS by another brominating agent, CuBr₂, gave the starting material unchanged (Table 1, entry 9). Reaction with NCS at 100 °C in CH₃CN only afforded the mono-chlorinated compound **1-Cl** as traces whereas the same reaction without palladium acetate in DMF only yielded untractable mixture of monochlorinated compounds.

Having the best experimental conditions (NIS, palladium acetate, MW heating at 100 °C for 15 minutes) in hand, we decided to check the scope and limitation of this iodination process on differently substituted benzodiazepinones (Table 2). Each starting material was synthesized from the corresponding aminobenzophenones^{20–21}.

It is worth noting that radioiodinated (¹²³I, ¹²⁵I or ¹³¹I) benzodiazepinones have been widely used in binding assays¹³. The strategies used in the synthesis of these radioiodinated benzodiazepinones always involve an isotopic exchange with Na¹²⁵I, the parent iodinated compound being synthesized from simple iodinated precursors such as iodobenzoic acid^{22–24}.

Our previously optimized iodinating conditions (Table 2, entry 1) allowed a clean conversion of the 7-bromo compound **2** into the monoiodinated compound **2-I** with 61% yield along with 3% of the diiodinated compound **2-II** (Table 2, entry 2). Notably, when one ortho position of the ring was




Table 2. Regioselective iodination of benzodiazepinones. ^aRatio were determined on isolated purified compounds. ^bYield calculated on ¹H NMR spectrum.




Figure 2. Crystal structure of compound 1-I.

already substituted slightly lower yield was experienced (Table 2, entry 3). Introduction of a methyl group on the 4' position does not alter the course of the reaction giving also fair yield and had no impact of the ratio of mono and diiodinated compounds **4-I** and **4-II** (Table 2, entry 4). Interestingly, the iodination also proceeds satisfactorily in the presence of a secondary amide (no methyl group on nitrogen 1) (Table 2, entry 5) even if the use of a benzyl protecting group allows the formation of the desired iodinated compound **7-I** with a better yield (Table 2, entry 7). Application of this protocol to a




Figure 3. Proposed CH activation based mechanism of benzodiazepinones iodination with Pd(OAc)₂.

drug was also envisioned. Therefore diazepam was submitted to NIS/Pd(OAc)₂ and clean conversion to the mono-iodinated analog **6-I** (Table 2, entry 6) was also successfully observed. It is worth precising here that this iodinated derivative showed higher receptor affinity than diazepam (IC₅₀ 0.74 nM versus 6.70 nM)²². Finally, the 4'-methylated analog afforded comparable yield and ratio of **8-I** and **8-II** compounds compared to unsubstituted benzodiazepinones (Table 2, entry 8). A copy of ¹H and ¹³C NMR spectra of all new compounds are available in the supplementary material from page S2 to S17.

The putative mechanism involves a CH activation assisted by the chelation of the nitrogen atom of the imino moiety of the benzodiazepinone. The insertion of a molecule of N-iodosuccinimide²⁵ allows the formation of complex **B** on which the Pd(II) was oxidized to Pd(IV). Then, ligand exchange provides dimeric intermediate **C** whose formation was confirmed by LC-MS. Finally, a reductive elimination occurs to afford mono-iodinated compound that can enter a new catalytic cycle to afford the diiodinated product (Fig. 3).

In this mechanism, we suggest that the oxidation of Pd(II) to Pd(IV) is prior to the ligand exchange step because the dimer formation, via a homoleptic complex, was not detected when benzodiazepine **1** was treated with Pd(OAc)₂ in the absence of NIS. Once we suggested the formation of complex **C** we investigated whether the dimer would be formed from a reductive elimination or a simple homocoupling from the iodinated compound. For this purpose the same reaction was performed starting from compound **1-I** and only non-iodinated dimer was formed strongly supporting the homocoupling process^{26–28}.

Conclusions

In conclusion, we have described herein an efficient protocol for regioselective halogenation of benzodiazepinones. This protocol takes advantage of CH activation with palladium acetate. Since radio-iodinated NIS is easily prepared, the CH activation described here offers a straightforward route to radioiodinated benzodiazepinones. Halogenated benzodiazepinones also represent ideal starting materials for more functionalized analogs via metal catalyzed cross-coupling reactions and this CH activation based approach opens new possibilities in this area. In this case, sequential halogenation/coupling procedures at the 7 then at the 2' position or vice versa could gain libraries of benzodiazepinones.

Methods

General remarks. The products were isolated by flash silica gel column chromatography (0.040–0.063 mm). Reactions were run without exclusion of air/moisture in a microwave tube. Reactions were monitored by NMR. ¹H and ¹³C NMR spectra were recorded using a Bruker Avance 400 MHz Ultrashield spectrometer in CD₃CN for all compounds except for compound **5-I** whose NMR analysis were conducted in (CD₃)₂SO for solubility reasons. The following abbreviations are used in reporting NMR data: s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; ddd, doublet of doublets of doublets; d appt, doublet of apparent triplet; m, multiplet. Infrared spectra were recorded on an FT-IR spectrophotometer. HPLC-MS analysis and purification were performed using a Waters system (2525 binary gradient module, in-line degasser, 2767 sample manager, 2996 Photodiode Array Detector) with a binary gradient solvent delivery system. This system was coupled with a Waters Micromass ZQ system with a

ZQ2000 quadrupole analyzer. The ionization was performed by electrospray and the other parameters were as follows: source temperature 120 °C, cone voltage 20 V, and continuous sample injection at 0.3 mL/min flow rate. Mass spectra were recorded in both positive and negative ion mode in the m/z 100–2,000 range and treated with the Mass Lynx 4.1 software. High-resolution mass spectrometry (HRMS) was performed using the Imagif platform (CNRS, Gif-sur-Yvette, France), and recorded on ESI/TOF LCP premier XE mass spectrometer (Waters) using flow injection analysis mode.

2'-iodo-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one (1-I). To a solution of 1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one **1** (30 mg, 0.12 mmol) in CD₃CN (1.2 mL), were added Pd(OAc)₂ (2.7 mg, 0.012 mmol) and N-iodosuccinimide (54 mg, 0.24 mmol). The mixture was stirred at 100 °C under microwave irradiation for 15 minutes. The crude mixture was evaporated, diluted in ethyl acetate (10 mL), and washed with a 2 M aqueous solution of NaOH (5 mL). The residue was purified by flash chromatography (cyclohexane/ethylacetate 1:1) affording 30 mg (69%) of **1-I** and 2 mg (3%) of **1-II**. IR (NaCl, cm⁻¹) 3057, 2988, 2850, 1676, 1611, 1573, 1489, 1449, 1361, 1324, 1280, 1201, 1167, 1128, 1076, 1046, 1014, 984, 939, 915; ¹H NMR (400 MHz, CD₃CN) δ 7.83 (d, $J = 8.0$ Hz, 1H, 3'-H), 7.56 (d appt, $J = 1.5$ Hz, $J = 8.7$ Hz, 1H, 8-H), 7.51–7.45 (m, 2H, 5'-H and 6'-H), 7.42 (d, $J = 8.2$ Hz, 1H, 9-H), 7.15 (ddd, $J = 9.2$ Hz, $J = 6.4$ Hz, $J = 2.8$ Hz, 1H, 4'-H), 7.09 (d appt, $J = 7.9$ Hz, $J = 0.9$ Hz, 1H, 7-H), 6.94 (dd, $J = 7.8$ Hz, $J = 1.4$ Hz, 1H, 6-H), 4.58 (d, $J = 10.6$ Hz, 1H, 3a-H), 3.76 (d, $J = 10.6$ Hz, 1H, 3b-H), 3.39 (s, 3H, 1-CH₃); ¹³C NMR (100 MHz, CD₃CN) δ 173.5 (C=N), 170.1 (C=O), 145.5 (C-1'), 140.3 (C-3'), 132.5 (C-8), 131.6 (C-4' and C-5' or C-6'), 130.1 (C-5a), 129.6 (C-6), 129.3 (C-6' or C-5'), 124.9 (C-7), 122.6 (C-9), 118.3 (C-9a), 96.8 (C-2'), 57.7 (C-3), 35.1 (1-CH₃); HR-MS (ESI+) m/z Calcd for C₁₆H₁₄N₂O [M+H⁺] 377.0151, Found 377.0145.

7-bromo-2'-iodo-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one (2-I). To a solution of 7-bromo-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one **2** (16 mg, 0.048 mmol) in CD₃CN (500 μL), were added Pd(OAc)₂ (1.1 mg, 0.0048 mmol) and N-iodosuccinimide (22 mg, 0.096 mmol). The mixture was stirred at 100 °C under microwave irradiation for 15 minutes. The crude mixture was evaporated, diluted in ethyl acetate (10 mL), and washed with a 2 M aqueous solution of NaOH (5 mL). The residue was purified by flash chromatography (cyclohexane/ethylacetate 1:1) affording 12 mg (54%) of **2-I** and 2 mg (7%) of **2-II**. IR (NaCl, cm⁻¹) 3059, 2985, 2920, 2853, 1678, 1613, 1584, 1559, 1480, 1421, 1399, 1343, 1320, 1275, 1249, 1196, 1167, 1129, 1075, 1045, 1015, 983, 942, 915; ¹H NMR (400 MHz, CD₃CN) δ 7.89 (d, $J = 7.8$ Hz, 1H, 3'-H), 7.56 (dd, $J = 8.8$ Hz, $J = 2.3$ Hz, 1H, 8-H), 7.61–7.49 (m, 2H, 5'-H and 6'-H), 7.38 (d, $J = 8.8$ Hz, 1H, 9-H), 7.23 (ddd, $J = 9.1$ Hz, $J = 7.8$ Hz, $J = 2.1$ Hz, 1H, 4'-H), 7.08 (d, $J = 2.3$ Hz, 1H, 6-H), 4.65 (d, $J = 10.9$ Hz, 1H, 3a-H), 3.76 (d, $J = 10.9$ Hz, 1H, 3b-H), 3.40 (s, 3H, 1-CH₃); ¹³C NMR (100 MHz, CD₃CN) δ 172.1 (C=N), 169.7 (C=O), 144.8 (C-1'), 140.4 (C-3'), 135.2 (C-8), 131.9 (C-4'), 131.8 (C-5' and C-6'), 129.4 (C-6), 124.8 (C-9), 118.3 (C-9a), 117.1 (C-7), 96.7 (C-2'), 57.7 (C-3), 35.0 (1-CH₃) ppm; HR-MS (ESI+) m/z Calcd for C₁₆H₁₃BrIN₂O [M+H⁺] 454.9256, Found 454.9265.

7-chloro-2'-iodo-6'-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one (3-I). To a solution of 7-chloro-6'-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one **3** (10 mg, 0.031 mmol) in CD₃CN (300 μL), were added Pd(OAc)₂ (0.7 mg, 0.003 mmol) and N-iodosuccinimide (14 mg, 0.062 mmol). The mixture was stirred at 100 °C under microwave irradiation for 15 minutes. The crude mixture was evaporated, diluted in ethyl acetate (10 mL), and washed with a 2 M aqueous solution of NaOH (5 mL). NMR and LC-MS analysis indicates a 50% conversion of the starting material to the desired compound **3-I**.

7-bromo-2'-iodo-4'-methyl-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one (4-I). To a solution of 7-bromo-4'-methyl-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one **4** (38 mg, 0.11 mmol) in CD₃CN (1.1 mL), were added Pd(OAc)₂ (2.5 mg, 0.011 mmol) and N-iodosuccinimide (50 mg, 0.22 mmol). The mixture was stirred at 100 °C under microwave irradiation for 15 minutes. The crude mixture was evaporated, diluted in ethyl acetate (10 mL), and washed with a 2 M aqueous solution of NaOH (5 mL). The residue was purified by flash chromatography (cyclohexane/ethylacetate 1:1) affording 28 mg (54%) of **4-I** and 4 mg (6%) of **4-II**. IR (NaCl, cm⁻¹) 3058, 2983, 2919, 2853, 1677, 1612, 1598, 1560, 1478, 1447, 1418, 1398, 1342, 1318, 1275, 1253, 1197, 1168, 1129, 1089, 1075, 1039, 1014, 983, 942, 916; ¹H NMR (400 MHz, CD₃CN) δ 7.73 (s, 1H, 3'-H), 7.70 (dd, $J = 8.8$ Hz, $J = 2.4$ Hz, 1H, 8-H), 7.43–7.32 (m, 3H, 9-H, 5'-H and 6'-H), 7.06 (d, $J = 2.3$ Hz, 1H, 6-H), 4.62 (d, $J = 10.7$ Hz, 1H, 3a-H), 3.79 (d, $J = 10.7$ Hz, 1H, 3b-H), 3.39 (s, 3H, 1-CH₃), 2.36 (s, 3H, 4'-CH₃); ¹³C NMR (100 MHz, CD₃CN) δ 172.0 (C=N), 169.8 (C=O), 144.7 (C-1'), 142.6 (C-4'), 140.8 (C-3'), 135.1 (C-8), 132.1 (C-5a), 131.9 (C-5' or C-6'), 131.6 (C-6), 130.1 (C-5' or C-6'), 124.7 (C-9), 118.3 (C-9a), 117.0 (C-7), 96.8 (C-2'), 57.7 (C-3), 35.0 (1-CH₃), 20.7 (4'-CH₃); HR-MS (ESI+) m/z Calcd for C₁₇H₁₅BrIN₂O [M+H⁺] 468.9412, Found 468.9427.

7-bromo-2'-iodo-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one (5-I). To a solution of 7-bromo-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one **5** (30 mg, 0.095 mmol) in CD₃CN (950 μL),

were added Pd(OAc)₂ (2.2 mg, 0.0095 mmol) and N-iodosuccinimide (43 mg, 0.19 mmol). The mixture was stirred at 100 °C under microwave irradiation for 15 minutes. The crude mixture was evaporated, diluted in ethyl acetate (10 mL), and washed with a 2 M aqueous solution of NaOH (5 mL). The residue was purified by flash chromatography (cyclohexane/ethylacetate 1:1) affording 17 mg (41%) of **5-I** and 2 mg (4%) of **5-II**. IR (NaCl, cm⁻¹) 3207, 3117, 2927, 2852, 1689, 1617, 1479, 1429, 1382, 1322, 1291, 1255, 1230, 1195, 1164, 1134, 1088, 1047, 1011, 945; ¹H NMR (400 MHz, (CD₃)₂SO) δ 10.82 (s, 1H, 1-H), 7.89 (d, *J* = 7.8 Hz, 1H, 3'-H), 7.71 (dd, *J* = 8.7 Hz, *J* = 2.3 Hz, 1H, 8-H), 7.52 (dt, *J* = 7.4 Hz, *J* = 0.8 Hz, 1H, 5'-H), 7.45 (dd, *J* = 7.5 Hz, *J* = 1.4 Hz, 1H, 6'-H), 7.22 (d appt, *J* = 7.8 Hz, *J* = 1.4 Hz, 1H, 4'-H), 7.18 (d, *J* = 8.7 Hz, 1H, 9-H), 6.96 (d, *J* = 2.2 Hz, 1H, 6-H), 4.19 (s, 2H, 3H); ¹³C NMR (100 MHz, (CD₃)₂SO) δ 170.7 (C = N), 169.1 (C = O), 143.7 (C-1'), 139.2 (C-5a), 139.1 (C-3'), 134.3 (C-8), 131.4 (C-6), 130.8 (C-4' and C-6'), 128.1 (C-5'), 123.1 (C-9), 114.3 (C-7), 96.9 (C-2'), 56.8 (C-3); HR-MS (ESI+) *m/z* Calcd for C₁₅H₁₁BrIN₂O [M+H⁺] 440.9099, Found 440.9090.

7-chloro-2'-iodo-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one (6-I). To a solution of 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one **6** (30 mg, 0.105 mmol) in CD₃CN (1.05 mL), were added Pd(OAc)₂ (2.4 mg, 0.010 mmol) and N-iodosuccinimide (47 mg, 0.210 mmol). The mixture was stirred at 100 °C under microwave irradiation for 15 minutes. The crude mixture was evaporated, diluted in ethyl acetate (10 mL), and washed with a 2 M aqueous solution of NaOH (5 mL). The residue was purified by flash chromatography (cyclohexane/ethylacetate 1:1) affording 26 mg (60%) of **6-I** and 2 mg (3%) of **6-II**. IR (NaCl, cm⁻¹) 3060, 2988, 2915, 2853, 1678, 1615, 1592, 1582, 1562, 1484, 1447, 1425, 1402, 1346, 1321, 1298, 1276, 1248, 1198, 1169, 1130, 1099, 1076, 1044, 1016, 983, 943, 916; ¹H NMR (400 MHz, CD₃CN) δ 7.89 (d, *J* = 7.8 Hz, 1H, 3'-H), 7.58 (dd, *J* = 8.8 Hz, *J* = 2.5 Hz, 1H, 8-H), 7.57–7.49 (m, 2H, 5'-H and 6'-H), 7.44 (d, *J* = 8.8 Hz, 1H, 9-H), 7.22 (d appt, *J* = 7.1 Hz, *J* = 2.2 Hz, 1H, 4'-H), 6.94 (d, *J* = 2.5 Hz, 1H, 6-H), 4.65 (d, *J* = 10.8 Hz, 1H, 3a-H), 3.85 (d, *J* = 10.8 Hz, 1H, 3b-H), 3.40 (s, 3H, 1-CH₃); ¹³C NMR (100 MHz, CD₃CN) δ 172.1 (C = N), 169.7 (C = O), 144.6 (C-1'), 140.4 (C-3'), 132.3 (C-8), 131.9 (C-4'), 131.8 (C-5' or C-6'), 131.5 (C-5a), 129.5 (C-7), 129.4 (C-6), 128.8 (C-5' or C-6'), 124.5 (C-9), 118.3 (C-9a), 96.8 (C-2'), 57.6 (C-3), 35.0 (1-CH₃); HR-MS (ESI+) *m/z* Calcd for C₁₆H₁₃ClIN₂O [M+H⁺] 410.9761, Found 410.9766.

Synthesis of 7-bromo-2'-iodo-1,3-dihydro-1-benzyl-5-phenyl-2H-1,4-benzodiazepin-2-one (7-I). To a solution of 7-bromo-1,3-dihydro-1-benzyl-5-phenyl-2H-1,4-benzodiazepin-2-one (30 mg, 0.074 mmol) in CH₃CN (740 μL), were added Pd(OAc)₂ (1.6 mg, 0.0074 mmol) and N-iodosuccinimide (33.5 mg, 0.148 mmol). The mixture stirred at 100 °C under microwave irradiation for 15 minutes under microwave irradiation. The crude mixture was evaporated, diluted in ethyl acetate (10 mL), and washed with a 2 M aqueous solution of NaOH (5 mL). The residue was purified by flash chromatography (cyclohexane/ethylacetate 1:1) affording 27 mg (69%) of **7-I** and 3 mg (6%) of **7-II**. IR (KBr, cm⁻¹) 3061, 3029, 2995, 2852, 1676, 1612, 1494, 1479, 1454, 1403, 1357, 1319, 1265, 1220, 1185, 1090, 1067, 1015, 938, 882; ¹H NMR (400 MHz, CD₃CN) δ 7.90 (d, *J* = 7.9 Hz, 1H, 3'-H), 7.62 (dd, *J* = 8.8 Hz, *J* = 2.1 Hz, 1H, 8-H), 7.50 (t, *J* = 7.5 Hz, 1H), 7.40–7.24 (m, 8H, 8-H, 9-H, 6'-H and Ph), 7.06 (t, *J* = 7.8 Hz, 1H, 4'-H), 7.09 (d, *J* = 2.3 Hz, 1H, 4'-H), 5.24 (d, *J* = 15.9 Hz, 1H, CH₂-Ph), 5.07 (d, *J* = 15.9 Hz, 1H, CH₂-Ph), 4.77 (d, *J* = 10.5 Hz, 1H, 3a-H), 4.01 (d, *J* = 10.5 Hz, 1H, 3b-H); ¹³C NMR (100 MHz, CD₃CN) δ 172.0 (C = N), 168.8 (C = O), 144.5 (C-1'), 140.6 (C-3'), 138.6 (C-5a), 135.3 (C-4), 132.3 (C-6), 132.2 (C-Ph), 131.9 (C-5' and C-6'), 132.0, 131.9, 129.7, 128.4, 128.3, 124.9 (Ph and C-9), 118.3 (C-9a), 117.6 (C-7), 96.8 (C-2'), 57.8 (C-3), 51.8 (CH₂-Ph); HR-MS (ESI+) *m/z* Calcd for C₂₂H₁₉BrIN₂O [M+H⁺] 530.9569, Found 530.9572.

2'-iodo-4'-methyl-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one (8-I). To a solution of 4'-methyl-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one **8** (30 mg, 0.11 mmol) in CD₃CN (1.1 mL), were added Pd(OAc)₂ (2.5 mg, 0.011 mmol) and N-iodosuccinimide (51 mg, 0.22 mmol). The mixture was stirred at 100 °C under microwave irradiation for 15 minutes. The crude mixture was evaporated, diluted in ethyl acetate (10 mL), and washed with a 2 M aqueous solution of NaOH (5 mL). The residue was purified by flash chromatography (cyclohexane/ethylacetate 1:1) affording 27 mg (61%) of **8-I** and 2 mg (3%) of **8-II**. IR (NaCl, cm⁻¹) 3057, 2982, 2920, 2852, 1674, 1598, 1572, 1481, 1447, 1360, 1323, 1280, 1203, 1166, 1128, 1076, 1040, 1010, 984, 939, 915; ¹H NMR (400 MHz, CD₃CN) δ 7.73 (s, 1H, 3'-H), 7.56 (d appt, *J* = 7.1 Hz, *J* = 1.4 Hz, 1H, 8-H), 7.48–7.30 (m, 3H, 9-H, 5'-H and 6'-H), 7.13 (appt, *J* = 7.2 Hz, 1H, 7-H), 7.97 (dd, *J* = 7.8 Hz, *J* = 1.3 Hz, 1H, 6-H), 4.59 (d, *J* = 10.6 Hz, 1H, 3a-H), 3.78 (d, *J* = 10.6 Hz, 1H, 3b-H), 3.42 (s, 3H, 1-CH₃), 2.35 (s, 3H, 4'-CH₃); ¹³C NMR (100 MHz, CD₃CN) δ 173.4 (C = N), 170.1 (C = O), 145.4 (C-1'), 142.2–142.5 (C-5a), 140.6 (C-3'), 132.4 (C-8), 131.3 (C-5' or C-6'), 130.3 (C-4'), 129.8–129.6 (C-6, C-5' or C'6), 124.8 (C-7), 122.5 (C-9), 118.2 (C-9a), 96.8 (C-2'), 57.7 (C-3), 34.9 (1-CH₃), 20.6 (4'-CH₃); HR-MS (ESI+) *m/z* Calcd for C₁₇H₁₆IN₂O [M+H⁺] 391.0307, Found 391.0320.

2'-bromo-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one (1-Br). To a solution of 1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one **1** (10 mg, 0.04 mmol) in DMF (400 μL), were added Pd(OAc)₂ (0.9 mg, 0.004 mmol) and N-bromosuccinimide (36 mg, 0.2 mmol). The mixture

was stirred at 100 °C under microwave irradiation for 60 minutes. The crude mixture was diluted in ethyl acetate (10 mL), and washed with a 2 M aqueous solution of NaOH (5 mL). The residue was purified by flash chromatography (cyclohexane/ethylacetate 1:1) affording 5 mg (35%) of **1-Br** and 4 mg (29%) of **3**. IR (NaCl, cm^{-1}) 3065, 2990, 2853, 1672, 1611, 1600, 1572, 1490, 1468, 1448, 1361, 1324, 1281, 1202, 1166, 1129, 1077, 1047, 1026, 1010, 985, 939, 915; ^1H NMR (400 MHz, CD_3CN) δ 7.62–7.55 (m, 3H, 3'-H, 8-H, 6'-H), 7.51 (d appt, $J = 7.4\text{ Hz}$, $J = 0.8\text{ Hz}$, 1H, 5'-H), 7.46 (d, 1H, $J = 8.1\text{ Hz}$, 9-H), 7.38 (ddd, $J = 9.4\text{ Hz}$, $J = 7.8\text{ Hz}$, $J = 1.8\text{ Hz}$, 1H, 4'-H), 7.14 (d appt, $J = 7.9\text{ Hz}$, $J = 0.8\text{ Hz}$, 1H, 7-H), 7.02 (dd, $J = 7.8\text{ Hz}$, $J = 1.4\text{ Hz}$, 1H, 6-H), 4.61 (d, $J = 10.6\text{ Hz}$, 1H, 3a-H), 3.81 (d, $J = 10.6\text{ Hz}$, 1H, 3b-H), 3.39 (s, 3H, 1- CH_3); HR-MS (ESI+) m/z Calcd for $\text{C}_{16}\text{H}_{14}\text{BrN}_2\text{O}$ [$\text{M} + \text{H}^+$] 329.0290, Found: 329.0286.

7-bromo-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one (2). To a solution of 1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one **1** (10 mg, 0.04 mmol) in DMF (400 μL), was added N-bromosuccinimide (36 mg, 0.2 mmol). The mixture was stirred at 100 °C under microwave irradiation for 60 minutes. The crude mixture was diluted in ethyl acetate (10 mL), and washed with a 2 M aqueous solution of NaOH (5 mL). The residue was purified by flash chromatography (cyclohexane/ethylacetate 1:1) affording 3.5 mg (27%) of **2** and 2.5 mg (25%) of recovered starting material **1**. IR (NaCl, cm^{-1}) 3061, 2922, 2852, 1679, 1608, 1480, 1446, 1397, 1339, 1321, 1269, 1198, 1179, 1129, 1090, 1072, 1017, 984, 941, 914; ^1H NMR (400 MHz, CD_3CN) δ 7.73 (dd, 1H, $J = 2.3\text{ Hz}$, $J = 8.8\text{ Hz}$, 8-H), 7.61–7.41 (m, 5H, 2'-H, 3'-H, 4'-H, 5'-H and 6'-H), 7.09–7.36 (m, 2H, 6-H and 9-H), 4.60 (d, $J = 10.9\text{ Hz}$, 1H, 3a-H), 3.78 (d, $J = 10.7\text{ Hz}$, 1H, 3b-H), 3.32 (s, 3H, 1- CH_3); HR-MS (ESI+) m/z Calcd for $\text{C}_{16}\text{H}_{14}\text{BrN}_2\text{O}$ [$\text{M} + \text{H}^+$] 329.0290, Found 329.0276.

Crystallographic data collection and structure determination. The data for compound **1-I** were collected at 150(2) K on a Nonius Kappa-CCD area detector diffractometer (Hoofst R.W.W: COLLECT: Data Collection Software. Edited by Nonius BV, Delft, The Netherlands; 1998.) using graphite-monochromated Mo-K α radiation ($\lambda = 0.71073\text{ \AA}$). The unit cell parameters were determined from ten frames, then refined on all data. The data (combination of φ - and ω -scans giving a complete data set up to $\theta = 30.5^\circ$ and a minimum redundancy of 4 for 90% of the reflections) were processed with HKL2000²⁹. Absorption effects were corrected empirically with the program SCALEPACK.2 The structure was solved by direct methods with SHELXS-97 and refined by full-matrix least-squares on F2 with SHELXL-97³⁰. All non-hydrogen atoms were refined with anisotropic displacement parameters. The hydrogen atoms were introduced at calculated positions and were treated as riding atoms with an isotropic displacement parameter equal to 1.2 times that of the parent atom (1.5 for CH_3).

Crystal data for compound 1-I. $\text{C}_{16}\text{H}_{13}\text{IN}_2\text{O}$, $M = 376.18$, monoclinic, space group P21/c, $a = 8.1056(3)$, $b = 12.9888(7)$, $c = 13.9601(7)\text{ \AA}$, $\beta = 98.725(3)^\circ$, $V = 1452.74(12)\text{ \AA}^3$, $Z = 4$, $D_c = 1.720\text{ g cm}^{-3}$, $\mu = 2.201\text{ mm}^{-1}$, $F(000) = 736$. Refinement of 182 parameters on 4430 independent reflections out of 53320 measured reflections ($R_{\text{int}} = 0.041$) led to $R_1 = 0.032$, $wR_2 = 0.085$, $S = 1.019$, $\Delta\rho_{\text{max}} = 0.82$, $\Delta\rho_{\text{min}} = -0.97\text{ e \AA}^{-3}$.

Note

[†]Electronic supplementary information (ESI) available: Experimental procedures and characterisation data for all products, including copies of ^1H and ^{13}C NMR spectra and X-ray structural information of **1-I** (CIF). CCDC 1014605.

References

- Fahey, D. R. The coordination-catalyzed ortho-halogenation of azobenzene. *J. Organometal. Chem.* **27**, 283–292 (1971).
- Du, B., Jiang, X. & Sun P. Palladium-Catalyzed Highly Selective ortho-Halogenation (I, Br, Cl) of Arylnitriles via sp^2 C–H Bond Activation Using Cyano as Directing Group. *J. Org. Chem.* **78**, 2786–2791 (2013).
- Wang, X.-C. et al. Pd(II)-Catalyzed C–H Iodination Using Molecular I_2 as the Sole Oxidant. *J. Am. Chem. Soc.* **135**, 10326–10329 (2013).
- Chu, L., Wang, X.-C., Moore, C. E., Rheingold, A. L. & Yu, J.-Q. Pd-Catalyzed Enantioselective C–H Iodination: Asymmetric Synthesis of Chiral Diarylmethylamines. *J. Am. Chem. Soc.* **135**, 16344–16347 (2013).
- Giri, R., Chen, X. & Yu, J.-Q. Palladium-Catalyzed Asymmetric Iodination of Unactivated C–H Bonds under Mild Conditions. *Angew. Chem. Int. Ed.* **44**, 2112–2115 (2005).
- Giri, R. et al. Catalytic and stereoselective iodination of prochiral C–H bonds. *Tetrahedron: Asymmetry* **16**, 3502–3505 (2005).
- Dubost, E., Fossey, C., Cailly, T., Rault, S. & Fabis, F. Selective ortho-Bromination of Substituted Benzaldoximes Using Pd-Catalyzed CH Activation: Application to the Synthesis of Substituted 2-Bromobenzaldehydes. *J. Org. Chem.* **76**, 6414–6420 (2011).
- Aiso, H. et al. Catalytic Electrochemical C–H Iodination and One-Pot Arylation by ON/OFF Switching of Electric Current. *J. Org. Chem.* **77**, 7718–7724 (2012).
- Kalyani, D., Dick, A. R., Anani, W. Q. & Sanford, M. S. Scope and selectivity in palladium-catalyzed directed C–H bond halogenation reactions. *Tetrahedron* **62**, 11483–11498 (2006).
- Stechmann, B. et al. Inhibition of retrograde transport protects mice from lethal ricin challenge. *Cell* **141**, 231–242 (2010).
- Gillet, D., Barbier, J., Davey, R., Cintrat, J.-C. & Noel, R., Inventors; CEA, University of Texas Medical Branch, assignees. 2, 3-Dihydroquinazolin-4(1H)-one derivatives for use in the treatment of viral infections. European patent EP 2722047 A1. 2014 April 23.
- Ming, X. et al. The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides. *Nucleic Acids Res.* **41**, 3673–3687 (2013).

13. Saji, H. *et al.* Yokoyama, A. An Approach for Assigning Benzodiazepine Receptor Binding with Radioiodinated Ligand: ¹²⁵I-labeled Diazepam Derivative. *Biol. Pharm. Bull.* **16**, 513–515 (1993).
14. Hadjipavlou-Litina, D. & Hansch, C. Quantitative Structure-Activity Relationships of the Benzodiazepines. *Chem. Rev.* **94**, 1483–1505 (1994).
15. Visnjevac, A. *et al.* Synthesis, Structural Characterisation and Biological Activity of Zn(II) and Pd(II) Complexes of 3-Substituted 5-(2'-pyridyl)-1,4-benzodiazepin-2-one Derivatives. *Polyhedron* **21**, 2567–2577 (2002).
16. Antolini, L. *et al.* Palladium (II) Complexes of 1,4-Benzodiazepines. Crystal Structure and Reactivity in Dimethylsulphoxide of [Pd(bromazepam)Cl₂]. *Polyhedron* **11**, 2795–2801 (1992).
17. Spencer, J. *et al.* C-H Activations on a 1H-1,4-Benzodiazepin-2(3H)-one Template. *Tetrahedron* **64**, 6082–6089 (2008).
18. Spencer J. *et al.* Synthesis and Evaluation of 5-Phenyl-1H-1,4-benzodiazepin-2(3H)-one-Based Palladium Complexes as Precatalysts in C-C Bond Forming Reactions. *Organometallics*. **24**, 5665–5672 (2005).
19. Pérez, J., Víctor, R., Rodríguez, A. & Miguel, D. Synthesis and Structure of the First Ruthenated Benzodiazepines. *Organometallics* **21**, 5437–5438 (2002).
20. Bourguignon, J.-J. *et al.* inventors; Neuro3D, Université Louis Pasteur, assignees. Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses. United States patent US 20060128695. 2006 June 15.
21. Mwanje-Maguene, G. *et al.* One-pot Microwave-assisted Synthesis and Antimalarial Activity of Ferrocenyl Benzodiazepines. *New J. Chem.* **35**, 2412–2415 (2011).
22. Katsifis, A., Mattner, F., Dikic, B., Najdovski, L. & Kassiou, M. Synthesis of Iodine-123 Labelled Analogues of Imidazenil and Ethyl-Imidazenil for Studying Benzodiazepine Receptors Using SPECT. *J. Label. Compd. Radiopharm.* **38**, 1121–1132 (1996).
23. Saji, H. *et al.* Radioiodinated 2'-Iodobenzodiazepam: A Potential Imaging Agent for SPECT Investigations of Benzodiazepine Receptors. *J. Nucl. Med.* **34**, 932–937 (1993).
24. Yurt, F., Unak, P., Ozkiliç, H. & Tuglular, I. Labeling of Diazepam with Iodine-131. *J. Radioanal. Nucl. Chem.* **200**, 75–83 (1995).
25. Crawforth, C. M. *et al.* Oxidative Addition of N-halosuccinimides to Palladium(0): the Discovery of Neutral Palladium(II) Imidate Complexes, which Enhance Stille Coupling of Allylic and Benzylic Halides. *Tetrahedron* **61**, 9736–9751 (2005).
26. Canty, A. J. Development of Organopalladium(IV) Chemistry: Fundamental Aspects and Systems for Studies of Mechanism in Organometallic Chemistry and Catalysis. *Acc. Chem. Res.* **25**, 83–90 (1992).
27. Dyker, G. Palladium-catalyzed annulation reactions of 1,8-dihydronaphthalene. *J. Org. Chem.* **58**, 234–238 (1993).
28. Hassan, J., Lavenot, L., Gozzi, C. & Lemaire, M. A Convenient Catalytic Route to Symmetrical Functionalized Bithiophenes. *Tetrahedron Lett.* **40**, 857–858 (1999).
29. Otwinowski, Z. & Minor, W. in *Methods in Enzymology*, Vol. 276: Macromolecular Crystallography, part A (eds Carter Jr., C. W.; Sweet, R. M.) 307–327, (Academic Press, 1997).
30. Sheldrick, G. M. A short history of SHELX. *Acta Crystallogr., Section A.* **64**, 112–122 (2008).

Author Contributions

H.A. and J.-C.C. designed the study. H.A. performed the experiments. H.A. and J.-C.C. analyzed the data. H.A. and J.-C.C. wrote and edited the manuscript. All authors reviewed and approved the manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Abdelkafi, H. and Cintrat, J.-C. Regioselective Halogenation of 1,4-Benzodiazepinones via CH Activation. *Sci. Rep.* **5**, 12131; doi: 10.1038/srep12131 (2015).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>